- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04565483
Assinatura Preditiva da Resposta ao Benralizumabe (BENRAPRED)
The objective of the study is to establish the predictive value of early blood gene expression signature of Benralizumab response associated with a significant reduction of the number of exacerbations in treated severe asthmatic patients.
This trial is a French, multicenter and no-randomized trial. Patients enrolled will be clinically followed for 16 months (the treatment period: 12 months and 1 month follow-up; 6 clinical visit on site and in phone call at 13 months)
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 4
Contactos e Locais
Locais de estudo
-
-
-
Aix-en-Provence, França
- Centre hospitalier Intercommunal Aix-en-Provence
-
Angers, França
- CHU Angers
-
Bordeaux, França
- CHU Bordeaux
-
Brest, França
- CHRU Brest
-
Dijon, França
- CHU Dijon
-
Grenoble, França
- CHU Grenoble
-
Le Kremlin-Bicêtre, França
- Hôpital Bicêtre - AP-HP
-
Le Mans, França
- CH Mans
-
Lille, França
- CHU Lille
-
Lyon, França
- Hospices Civils de Lyon
-
Marseille, França
- Assistance Publique des Hôpitaux de Marseille
-
Montpellier, França
- CHU Montpellier
-
Nantes, França
- CHU Nantes
-
Orléans, França
- CHR Orléans
-
Paris, França
- Hôpital Bichat - AP-HP
-
Rouen, França
- CHU Rouen
-
Strasbourg, França
- CHU Strasbourg
-
Suresnes, França
- Hôpital FOCH
-
Toulouse, França
- CHU Toulouse
-
Villeurbanne, França
- Médipôle Hôpital Mutualiste de Villeurbanne
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Patients between 18 and 75 years old.
-
Patients diagnosed with severe asthma (Chung and al, Eur Respir J 2014), i.e.:
- asthma requiring high doses of ICS (>1000 microgram per day of Beclomethasone or equivalent) associated with LABA and/or systemic corticosteroids to be controlled over one year,
- and/or uncontrolled asthma despite the later medications,
- and/or a controlled asthma worsening after decreasing medications,
-
Documented historical reversibility of FEV1 ≥12% and FEV1 gain ≥ 200 milliliter
-
ACQ-7 score ≥ 1,5 at M0.
-
≥ 3 exacerbations in the 12 months prior to screening visit M-1.
-
Eosinophil blood count ≥ 0,3 G/L at inclusion visit or in the 12 months prior to the inclusion visit. If eosinophil blood count is ≥ 0,15 G/L and < 0,3 G/L, an eosinophilic phenotype defined by at least 1 of the following criteria will be required:
- Fractional Exhaled Nitric Oxide (FeNO) > 25 ppm at inclusion visit or in the 12 months prior to the inclusion visit.
- Sputum eosinophils ≥ 3% at inclusion visit or in the 12 months prior to the inclusion visit.
-
Patients who provide written informed consent prior to participation in the study
Exclusion Criteria:
- Patients diagnosed with difficult-to-treat asthma and/or with uncontrolled asthma differential diagnosis according to the judgment of the investigator (e.g., vocal cord dysfunction, gastroesophageal reflux disease, granulomatous eosinophilic vasculitis, obstructive sleep apnea syndrome, hyperventilation syndrome, allergic broncho-pulmonary aspergillosis, Carrington disease, DIPNECH, asthma/COPD overlap syndrome).
- Non-adherent patients to inhaled treatment (ICS + LABA).
- Active smokers or former smokers exceeding 20 packs year.
- Exacerbation at inclusion visit M0.
- Active malignancy or malignancy in remission over less than 5 years.
- Active parasitic infection or parasitic infection in the past 24 weeks.
- Hypersensitivity to Benralizumab or to any of the excipients of Fasenra® (histidine, histidine hydrochloride monohydrate, trehalose dihydrate, polysorbate 20)
- Patients requiring other immunosuppressive and immunomodulator drugs
- Patients requiring other biotherapy than Benralizumab, with or without French's marketing authorisation in severe asthma
- Patients requiring other biotherapy than Benralizumab that affects the immune system
- SARS-COV2 infection
- Pregnancy, lactation, or patients with childbearing potential refusing efficient contraceptive method.
- Patients under psychiatric condition altering their comprehension and their ability to give informed consent.
- Patients already enrolled in a clinical interventional research.
- Patients not affiliated to a health insurance plan
- Patients under guardianship, curators or safeguard of justice
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Outro
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: BENRALIZUMAB
Patients receive BENRALIZUMAB if they meet the criteria for inclusion and non-inclusion at the inclusion visit. Injections take place at the inclusion visit, at 1 month, 2 months, 4 months, 6 months, 8 months, 10 months and 12 months. |
Patients receive BENRALIZUMAB if they meet the criteria for inclusion and non-inclusion at the inclusion visit. Injections take place at the inclusion visit, at 1 month, 2 months, 4 months, 6 months, 8 months, 10 months and 12 months.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Predictive value of early blood gene expression signature of Benralizumab
Prazo: 12 months
|
To establish the predictive value of early blood gene expression signature of Benralizumab response associated with a significant reduction of the number of exacerbations in treated severe asthmatic patients. We will evaluate an early blood gene expression signature of Benralizumab response through a clinically relevant reduction of the number of exacerbations at month 12 (M12). |
12 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Molecular signature predictive of stabilization
Prazo: 12 months
|
To establish at M0 (baseline) a molecular signature predictive of stabilization in severe asthmatic patients treated by Benralizumab. At M0 a composite blood molecular signature predictive of reduction of the exacerbation rate at M12 in severe asthmatic patients treated by Benralizumab will be assessed. The definition of stable class of patients (low category) is used as a target for the prediction. The methods used for the primary objective are applied to secondary objective using similar input data on a different 3-class prediction target. |
12 months
|
|
The stability of the signature over time
Prazo: 0 month, 3 months, 6 months and 9 months
|
To evaluate the stability of the signature over time (from early at M0, M3, to late prediction at M6 and M9) considering patient trajectories. The significance of center and the relevance of time dependent modelling will be evaluated using generalised mixed models on independently established molecular response signature. It is expected a robust and reproducible gene expression to assess the inter and intra-individual trajectories of the signature over time and across centers (from early at M0 and M3, to late prediction at M6 and M9). |
0 month, 3 months, 6 months and 9 months
|
|
The association of gene expression patterns
Prazo: 12 months
|
To evaluate the association of gene expression patterns with both objective and subjective improvement. Correlations network between blood gene expression of Benralizumab significant response will be assessed thanks to weighted gene correlation network analysis (gene co-expression network analysis (WGCNA)) with an expected increase in forced expiratory volume at one second (FEV1) + Asthma Quality of Life Questionnaire (AQLQ) + peak-flow values and expected decrease of Asthma Control Questionnaire-7 items (ACQ-7), -6 items (ACQ-6) scores. |
12 months
|
|
Association of gene expression patterns and clinical characteristics
Prazo: 0 months
|
To evaluate association of gene expression patterns at M0 (baseline) and clinical characteristics of frequent exacerbations. Correlations network between blood gene expression at M0 and clinical characteristics of frequent exacerbations will be assessed thanks to WGCNA. |
0 months
|
|
Stratification value of gene expression in severe asthma
Prazo: 12 months
|
To assess the stratification value of gene expression in severe asthma and its correlation with clinical subgroups and clinically meaningful variables such as number of exacerbations. Correlation network between stratification value of gene expressions in severe asthma and its correlation with clinical subgroups will be assessed thanks to WGCNA. This analysis is based on pairwise correlations between genetic variables and clinical variables underlying the amount of overall variance captured by high dimensional gene expression datasets. |
12 months
|
|
Scenario-based cost-utility analysis
Prazo: 12 months
|
To conduct a scenario-based cost-utility analysis.Concerning cost-utility analysis, two strategies of treatment with Benralizumab will be compared: the first one will consider a strategy not using an early blood gene expression signature of Benralizumab response and the second will consider a simulated strategy using an early blood gene expression signature of Benralizumab response. |
12 months
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças do sistema imunológico
- Doenças Respiratórias
- Doenças pulmonares
- Doenças brônquicas
- Doenças Pulmonares Obstrutivas
- Hipersensibilidade Respiratória
- Hipersensibilidade, Imediata
- Hipersensibilidade
- Síndrome Hipereosinofílica
- Eosinofilia
- Distúrbios leucocitários
- Doenças Hematológicas
- Doenças hemic e linfáticas
- Asma
- Eosinofilia Pulmonar
Outros números de identificação do estudo
- RC19_0292
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .